Welcome to our dedicated page for Applied UV news (Ticker: AUVI), a resource for investors and traders seeking the latest updates and insights on Applied UV stock.
Applied UV, Inc. (AUVI) delivers innovative UV-based disinfection systems and custom mirror solutions for healthcare and hospitality sectors. This page provides investors and industry professionals with direct access to official announcements, financial updates, and strategic developments from the company.
Find timely updates on product launches, regulatory milestones, and partnership agreements that shape AUVI’s position in smart building technology and infection control markets. Content includes earnings reports, technology patents, and market expansion initiatives, offering insights into the company’s operational priorities.
Bookmark this page to stay informed about AUVI’s advancements in automated sterilization systems and decorative mirror designs. Regular updates ensure you never miss critical information affecting the company’s performance across global healthcare and hospitality markets.
Applied UV (NASDAQ:AUVI) announced the installation of its Airocide® air purification units at the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand. This initiative aims to enhance safety against airborne pathogens, particularly amid concerns over COVID-19 and the emerging Omicron variant. Airocide® technology, recognized as an FDA Class II Medical Device, has proven efficacy in eliminating airborne pathogens. The installation reflects the commitment of the medical community in Thailand to adopt advanced air purification systems.
Applied UV (NasdaqCM:AUVI) announced a cash dividend of $0.21875 per share for its 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP). This dividend will be distributed on or around December 15, 2021, to shareholders on record as of December 3, 2021. The company specializes in infection control technology utilizing UVC light and bioconversion methods for air purification, catering to healthcare and commercial markets.
Applied UV reported a significant 88.5% increase in revenue to $3.55 million for Q3 2021, compared to $1.88 million in the previous quarter. Gross profit rose to $1.0 million, or 29.6% versus sales. The net loss improved by 49% to $(1,080,805), with net loss per share improving to $(0.14). The company continues to execute its growth strategy through acquisitions, including KES and Scientific Air Management, which are expected to add $10-14 million in annual revenues. As of September 30, Applied UV had approximately $11.7 million in cash on hand.
MOUNT VERNON, NY / ACCESSWIRE / November 11, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) announces an investor conference call on November 16, 2021, at 9:00 am ET to discuss its third quarter 2021 financial results. The call can be accessed via the company's website or by phone. Interested parties can dial +1-888-506-0062 for domestic calls or +1-973-528-0011 for international attendees, using passcode 933198. A replay will be available for one week following the call. Applied UV focuses on infection control technologies, offering solutions for various sectors including healthcare and hospitality.
Applied UV (NasdaqCM:AUVI) has announced a cash dividend of $0.21875 per share for its 10.5% Series A Cumulative Perpetual Preferred Stock. The dividend will be distributed on or about November 15, 2021, to stockholders on record as of November 4, 2021. This announcement reflects the company's ongoing commitment to providing returns to its preferred shareholders. Applied UV specializes in infection control technology, utilizing ultraviolet light for disinfection.
Applied UV (NasdaqCM: AUVI) has announced that its Airocide® Air Purification System can kill the multi-drug resistant fungus Candida auris based on preliminary lab results. According to the CDC, C. auris has a high mortality rate, with 30-60% of bloodstream infection cases resulting in death. The company's technology, recognized for its efficacy in air purification, aims to address significant health challenges, especially in hospitals. With recent acquisitions, Applied UV targets the healthcare and commercial markets, reinforcing its commitment to infection control and improving air quality.
Applied UV has announced the acquisition of Scientific Air Management for $9.5 million in cash and 400,000 shares, enhancing its infection control technology portfolio. This acquisition is set to add $5-$7 million in annual revenue and is expected to be EBITDA positive in Q1 2022. Applied UV aims to deepen its market penetration and expand its product offerings in the healthcare sector. The deal complements previous acquisitions and strengthens its capability to address healthcare-associated infections (HAIs) through advanced air purification technologies.
Applied UV (NasdaqCM:AUVI) has announced the installation of Airocide units in multiple wineries across Mexico by its exclusive distributor, JARO Trading and Supply. This technology helps control mold and pathogens, creating safer environments for staff and visitors. The system, already trusted in North America and Europe, is crucial for maintaining wine quality by preventing mold on barrels. The company reports improving sales activity in Latin America, highlighting the growing adoption of their air purification solution.
Applied UV (NasdaqCM:AUVI) announced independent lab results confirming that its Airocide HD Air Purification System effectively kills SARS-CoV-2 virus in the air. Conducted by MRIGlobal, tests showed a 99.94% reduction of the virus within 5.5 minutes. The system combines UVC light with a titanium dioxide-based photocatalyst and is listed as an FDA Class II Medical device. CEO Q Saeed emphasized the importance of air purification in mitigating COVID-19 risks, suggesting Airocide as part of a broader protective strategy for various environments.
FAQ
What is the current stock price of Applied UV (AUVI)?
What is the market cap of Applied UV (AUVI)?
